Prescribing overview
Current Vasotec information is human labeling. Historical Enacard identity does not verify a currently approved U.S. canine product.
Key prescribing checks
- Review hydration, blood pressure, creatinine and potassium when considering therapy or follow-up. Excessive blood-pressure reduction and renal effects require clinical assessment.
- Check potassium supplements, potassium-sparing drugs, diuretics and NSAIDs during reconciliation; these can alter the safety of ACE-inhibitor therapy.
- The human label includes fetal-toxicity warnings. Reproductive status and animal-specific references must be reviewed rather than assuming cross-species safety.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Humans; current animal label not verified
Human prescription labelHypertension and selected heart-failure indications
Do not transfer human approval or dosing to dogs.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Enalapril's active metabolite enalaprilat inhibits ACE, reducing angiotensin II formation.
Absorption, distribution, metabolism and elimination
The human label describes conversion to enalaprilat and renal elimination; no animal half-life is inferred.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Enacard
Historical U.S. canine tablets; no current brand safety label verified.
Contraindications · when not to use
A formal contraindication list is not established in the reviewed source for this scope. This does not establish safety; confirm the exact product and full labeling.
Precautions & monitoring
- Needs current label safety review before any product-specific decision.
Vasotec
Human enalapril tablets; these restrictions do not establish animal contraindications.
Contraindications · when not to use
- Product hypersensitivity; prior ACE-inhibitor-related, hereditary or idiopathic angioedema; aliskiren in diabetic patients; neprilysin inhibitors, including the required 36-hour separation from sacubitril/valsartan.
Precautions & monitoring
- Fetal toxicity warning; assess pregnancy, hypotension/volume depletion, renal function and potassium.
Enacard coverage remains explicitly unresolved for product-specific safety; do not apply the human Vasotec label as a canine Enacard label.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Human warnings include hypotension, hyperkalemia, renal dysfunction and angioedema; these are not animal incidence estimates.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
Current approved veterinary dose not verified; historical Enacard regimens and human doses intentionally omitted.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Vasotec
Human enalapril tablets; these restrictions do not establish animal contraindications.
- Review potassium supplements/sparing diuretics, other renin-angiotensin-system inhibitors, diuretics, NSAIDs, lithium and mTOR inhibitors.
Monitoring
Veterinary prescriber should assess blood pressure, renal function, potassium and concurrent drugs.
Client counseling
Do not replace a veterinary prescription with human package directions; report collapse or marked weakness.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Follow the exact dispensed product's instructions.
Brands, formulations & ingredient identity
Active ingredients
enalapril maleate
Enacard remains a useful historical brand synonym. FDA’s June 2024 Green Book update records withdrawal of its approval because it was no longer manufactured or marketed; do not present it as a currently available U.S. veterinary brand.
Vasotec is a human tablet product. The shared enalapril maleate ingredient does not make its human instructions a canine prescription.
Enalaprilat is the active metabolite and also exists as a separately labeled injectable drug. It is not a dispensing synonym for oral enalapril.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Enacard
- Formulation
- Historical oral tablets
- Label / product scope
- Dogs
U.S. approval withdrawn in 2024 because no longer manufactured or marketed.
Product label / source ↗Vasotec
- Formulation
- Oral tablets
- Label / product scope
- Human product
Human enalapril maleate brand; animal use requires veterinary prescribing.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.